ResourcesAmerican Society of Clinical Oncology (ASCO) American Society of Hematology (ASH) Association of Community Cancer Centers (ACCC) Community Oncology Alliance (COA) Institute for Clinical Immuno-Oncology (ICLIO) National Comprehensive Cancer Network (NCCN) Oncology Foundation of Maryland/DC Why the Patient Voice MattersRecently Bristol Myers Squibb’s U.S. Policy & Government Affairs team held an interactive discussion with state & federal policymakers on the importance of the patient voice in the legislative process. The forum provided an opportunity for attendees to hear directly from current legislators as they provided their insights on effective advocacy strategies and engagement with elected officials. During the discussion, the panelists shared what they seek to learn when meeting with advocates, first-hand examples of advocacy campaigns that have impacted their decision-making, tips for virtual advocacy engagement, and advice for any advocate looking to get involved in the legislative process. To listen to this recent webinar please use the following link: Why the Patient Voice Matters: Legislator Roundtable Forum (virtualpolicyforum.com)
|
Corporate Members
Affiliates
June 2022 Issue
MDCSCO Insights
Click here for past issues of Strategies
Click here to advertise in Strategies
CALL TO ACTION: Clinical Treatment Act Implementation
Beginning on January 1, 2022, all states and territories will be required to cover and reimburse for the routine costs of care for services associated with Medicaid enrollee participation in a qualifying clinical trial. The Center for Medicaid and CHIP Services (CMCS) issued a State Medicaid Director Letter outlining new Medicaid state plan requirements, including what is/is not a covered service, definition of a qualifying clinical trial, coverage determinations, and state exceptions for compliance as presented in the legislation.
CMCS is instructing states to submit a state plan amendment (SPA) describing coverage, benefits, and payment methodology used to pay service providers for routine costs associated with clinical trials in each state. The SPA should be issued at least one day prior to the effective date of the proposed changes. To ensure equitable, transparent, consistent, and comprehensive coverage requirements across all states, ASCO drafted a SPA offering specific and technical coverage and reimbursement recommendations. The SPA is intended to serve as a model submission from state Medicaid agencies to CMCS. We have also attached an accompanying "challenges" document which provides the rationale for the provisions included in the SPA and other implementation considerations.
We urge State Affiliates to send the attached SPA and challenges document to your State Medicaid Agency requesting they consider our recommendations as they draft their own. With the CLINICAL TREATMENT Act effective in less than two weeks, we recommend sending this as soon as possible. Please contact Gina Hoxie at [email protected] with any questions or for additional information.